In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological disorders increased significantly ...

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

The causal relationship of liver disease to neuropathy has been questioned. This study was designed to evaluate the incidence and character of peripheral neuropathy in patients with liver cirrhosis.

The new findings show that ADCs, just like chemotherapy ... contributing to chemotherapy-induced peripheral neuropathy. ADCs, ...

A team of international researchers including those from the University of Adelaide have taken a well-known chemical reaction ...

and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. - Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug ...

Just over a year after its first phase 3 trial of its Engensis gene therapy for painful diabetic peripheral neuropathy (DPN) bombed, Helixmith has started dosing patients in a new study.

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 2021 that ...

London - Abu Dhabi – Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful ...